MES1022 Drug Conjugate
MES1022 is a drug-conjugate consisting of two parts:
1. the Targeting moiety, and
2. the Drug moiety.
The targeting moiety is a novel proprietary molecule that has high-affinity to bone. The drug moiety is a prostaglandin mimetic that acts on PGE2 receptor 4 (EP4) released from the conjugate with a half-life of 7 days.
MES1022 uses a modified alendronic acid as a targeting moiety for its property of high-affinity to bone. It has no biological activity. Mesentech's drugs work through the prostaglandin pathway and are anabolic.
How it works
The MES1022 drug-conjugate carries the drug in an inactive state until it binds to the bone. After the targeting moiety binds to bone, the drug is released where it is received by stem cells, stimulating their maturation to osteoblasts (bone-making cells).
1. Targeting moiety facilitates targeting of conjugate to bone (inactive until it binds to bone)
2. Conjugate bond breaks with half-life of ~7 days, releasing the active drug into the bone
3. EP4 agonist stimulates mesenchymal stem cell differentiation to osteoblasts
4. Bone growth mimics natural process, without overgrowth
How safe is it?
MES1022 avoids systemic exposure and side effects by specifically delivering drugs to the bone.
We have completed GLP toxicity studies in NHPs. It is well tolerated and there were no unexpected toxicity findings.
